

NEUROPATHIE ENTERIQUE (ENTERIC NEUROPATHY) - Enteric Neuropathy

Head : Bourreille Arnaud, INSTITUT DES MALADIES DE L'APPAREIL DIGESTIF (IMAD). SERVICE DE GASTRO-ENTEROLOGIE ET D'ASSISTANCE NUTRITIONNELLE.

Last update : 05/13/2015 | Version : 1 | ID : 5972

General

Identification

Detailed name Enteric Neuropathy

Sign or acronym NEUROPATHIE ENTERIQUE (ENTERIC NEUROPATHY)

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation Date of receipt favourable opinion from CNIL: 01/01/2008

General Aspects

Medical area Gastroenterology et hepatology
Neurology

Health determinants Genetic

Keywords phenotypic data, demographic data, computerised data bank, biotherapy, steroid dependence, rheumatic, skin, eye and vascular extra-digestive symptoms, hospital stays, immunosuppressants, health events, consultation, diagnosis, surgery, liver

Scientific investigator(s) (Contact)

Name of the director Bourreille

Surname Arnaud

Address 44093 NANTES CEDEX

Phone + 33 (0)2 40 08 31 52 ou +33 (0)2 40 08 79 25

Email arnaud.bourreille@chu-nantes.fr

Unit INSTITUT DES MALADIES DE L'APPAREIL DIGESTIF (IMAD). SERVICE DE GASTRO-ENTEROLOGIE ET D'ASSISTANCE NUTRITIONNELLE.

Organization

UMR INSERM U913 CHU

Collaborations

Funding

Funding status

Public

Details

CHU Nantes DRCI (Clinical Research and Innovation Delegation) and AAP DHOS-INSERM

Governance of the database

Sponsor(s) or organisation(s) responsible

CHU Nantes

Organisation status

Public

Additional contact

Main features

Type of database

Type of database

Study databases

Study databases (details)

Cohort study

Database recruitment is carried out as part of an interventional study

No

Additional information regarding sample selection.

Prospective Other bodies active in creating this cohort: CHU, INSERM UMR 913 AND CIC-04 GASTROESOPHAGEAL NUTRITION AND NEUROLOGY FIELD

Database objective

Main objective

General objective: to develop and expand the cohort and enteric neuropathy biological collection for patients with IBD and Parkinson's disease (PD).
Secondary objectives:
- Transcriptomic study of neuronal and glial plasticity;
- Study and classification of neuro-degenerative processes;
- Correlation of neuronal damage with clinical parameters and outlook.

Inclusion criteria

Enrolment includes all adult patients with IBD and PD monitored by the CHU in Nantes. Patients will be

enrolled at time of diagnosis. Patients will be enrolled after disease diagnosis if phenotypic data included in the database are available in the source file. Blood will be taken during sampling in order to monitor patient disease. Biopsy samples will be taken during endoscopic examinations for conventional disease monitoring. Exclusion criteria: underage patients, absence of study participation consent, lost to follow-up, phenotypic data not available from source file, PD patients with no digestive disorder requiring an endoscopy.

Population type

Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years)
-----	--

Population covered	Sick population
--------------------	-----------------

Gender	Male Woman
--------	---------------

Geography area	Regional
----------------	----------

French regions covered by the database	Pays de la Loire
--	------------------

Detail of the geography area	Pays de la Loire region
------------------------------	-------------------------

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)	2009
--	------

Size of the database

Size of the database (number of individuals)	< 500 individuals
--	-------------------

Details of the number of individuals	100 IBD patients and 30 PD patients were included in the biological collection. These patients are part of the historical cohort. Phenotypic data is entered in the electronic database.
--------------------------------------	--

Data

Database activity	Data collection completed
-------------------	---------------------------

Type of data collected	Clinical data
------------------------	---------------

	Declarative data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Details of collected clinical data	Clinical examination at baseline and every 6 months during follow-up. Information collected during clinical examination: items are filled out during interview. Items correspond to those in the database. Patients are followed up every 6 months and an interview is carried out at every additional visit. Item details were previously entered.
Declarative data (detail)	Face to face interview
Details of collected declarative data	Interview questionnaire at baseline and every 6 months during follow-up.
Biological data (detail)	Type of samples taken: blood samples (serum 10 ml and 10 ml whole blood) colonic (x6) and/or gastroesophageal biopsies (x4)
Presence of a biobank	Yes
Contents of biobank	Serum Tissues DNAc/RNAc
Details of biobank content	Serum bank, tissue bank, cNAD from colonic biopsy tRNA
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services
Care consumption (detail)	Hospitalization Medicines consumption
Procedures	
Data collection method	Interview: direct input Clinical examinations: direct input Biological analysis: direct input
Quality procedure(s) used	Consistency request after electronic data is recorded. Missing data is managed by returning to source file. Physician reminder for follow-up visits. Subject reminder for follow-up visits. Annual internal quality audit of database with 10% file analysis. Patients are informed about the use of their data.
Participant monitoring	Yes

Details on monitoring of participants

(Indefinite duration)

Links to administrative sources

No

Promotion and access

Promotion

Access

Terms of data access (charter for data provision, format of data, availability delay)

Data may be used by academic teams.
Access conditions for biological collection are part of the Biobanque Ouest Atlantique (BOA, Western Atlantic Biobank) pending GIS-IBiSA certification request. Data will be available to other institutional research teams under contract.
Data may be used by industrial teams.
Access conditions for biological collection are part of the Biobanque Ouest Atlantique (BOA, Western Atlantic Biobank) pending GIS-IBiSA certification request. Data will be available to other private research teams under contract with CHU.

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only